<p>Adage Capital Partners GP L.L.C. 在最近向美国证券交易委员会提交的 13F 表格中表示，在第一季度将其在史赛克公司（NYSE:SYK - 免费报告）的持股减少了 7.0%。该公司在季度内出售了 10,044 股后，持有 134,347 股这家医疗科技公司的股票。Adage Capital Partners GP L.L.C. 在史赛克的持股在最近一个季度末价值为 50,011,000 美元。</p>
<ul>
<li>如果你只能持有 3 项投资一辈子，请考虑这些</li>
</ul>
<p>其他几家机构投资者最近也对其在 SYK 的持仓进行了调整。Elefante Mark B 在第四季度购买了约 337,000 美元的新股份。Mogy Joel R Investment Counsel Inc. 在第一季度将其在史赛克的持股增加了 3.4%。Mogy Joel R Investment Counsel Inc. 现在持有 98,216 股这家医疗科技公司的股票，价值 36,561,000 美元，此前在上个季度又购买了 3,218 股。Ferguson Wellman Capital Management Inc. 在第一季度将其在史赛克的持股增加了 1.9%。Ferguson Wellman Capital Management Inc. 现在持有 174,871 股这家医疗科技公司的股票，价值 65,096,000 美元，此前在上个季度又购买了 3,341 股。Harbor Capital Advisors Inc. 在第一季度购买了约 1,840,000 美元的新股份。最后，Mar Vista Investment Partners LLC 在第一季度将其在史赛克的持股增加了 10.2%。Mar Vista Investment Partners LLC 现在持有 90,187 股这家医疗科技公司的股票，价值 33,572,000 美元，此前在上个季度又购买了 8,353 股。机构投资者目前持有该公司 77.09% 的股票。</p>
<h2>内部买卖</h2>
<p>在其他史赛克的新闻中，董事 Ronda E. Stryker 于 8 月 6 日星期三出售了 200,000 股公司的股票。该股票以平均价格 376.45 美元出售，总交易额为 75,290,000.00 美元。交易后，该董事在公司持有 3,222,108 股，估值约为 1,212,962,556.60 美元。这代表其持股减少了 5.84%。该交易已在向证券交易委员会的法律文件中披露，相关信息可通过 SEC 网站获取。此外，内部人士 Viju Menon 于 8 月 25 日星期一出售了 500 股公司的股票。该股票以平均价格 390.61 美元出售，总价值为 195,305.00 美元。交易后，该内部人士在公司持有 12,511 股，估值为 4,886,921.71 美元。这笔交易代表其持股减少了 3.84%。该销售的披露信息可以在这里找到。当前 5.20% 的股票由公司内部人士持有。</p>
<h2>史赛克股票表现</h2>
<ul>
<li>3 只股票助力人工智能进入医疗保健领域</li>
</ul>
<p>史赛克股票在星期四开盘价为 388.14 美元。该公司的流动比率为 1.78，速动比率为 1.06，债务与股本比率为 0.70。该公司的 50 日移动平均线为 389.48 美元，200 日移动平均线为 379.51 美元。该公司的市值为 1483.9 亿美元，市盈率为 51.41，市盈增长比率为 2.85，贝塔值为 0.93。史赛克公司的 1 年最低价为 329.16 美元，1 年最高价为 406.19 美元。</p>
<p>史赛克（NYSE:SYK - 获取免费报告）最近一次发布财报是在 7 月 31 日星期四。这家医疗科技公司报告本季度每股收益为 3.13 美元，超出分析师一致预期的 3.07 美元，超出幅度为 0.06 美元。史赛克的净利润率为 12.25%，股本回报率为 23.94%。该公司本季度的收入为 60.2 亿美元，而分析师预期为 59.2 亿美元。在去年同期，该公司每股收益为 2.81 美元。史赛克本季度的收入同比增长 11.1%。史赛克已将其 2025 财年的每股收益指导设定为 13.400-13.600。卖方分析师预计史赛克公司本年度将发布 13.47 的每股收益。</p>
<h2>史赛克宣布分红</h2>
<ul>
<li>波士顿科学：为什么这家医疗科技巨头不会放慢脚步</li>
</ul>
<p>该公司最近还宣布了一项季度分红，将于 10 月 31 日星期五支付。9 月 30 日星期二的股东将获得每股 0.84 美元的分红。除息日为 9 月 30 日星期二。这代表年化分红为 3.36 美元，分红收益率为 0.9%。史赛克的分红支付比率为 44.50%。</p>
<h2>分析师设定新目标价</h2>
<p>几家券商已对 SYK 发布了报告。华尔街 Zen 在 7 月 18 日星期五的研究报告中将史赛克的评级从 “持有” 上调至 “买入”。Needham &amp; Company LLC 在 8 月 1 日的研究报告中将史赛克的目标价从 442.00 美元上调至 448.00 美元，并给予该公司 “买入” 评级。BTIG Research 在 7 月 14 日星期一的研究报告中重申了对史赛克股票的 “买入” 评级。花旗集团在 5 月 22 日星期四的研究报告中重申了 “买入” 评级，并将史赛克股票的目标价设定为 455.00 美元（上调自 443.00 美元）。最后，Evercore ISI 在 7 月 8 日星期二的研究报告中将史赛克的目标价从 390.00 美元上调至 415.00 美元，并给予该公司 “跑赢大盘” 评级。十五位研究分析师对该股票给予了 “买入” 评级，四位给予了 “持有” 评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “适度买入”，共识目标价为 430.10 美元。</p>
<p><strong>阅读我们最新的 SYK 股票报告</strong></p>
<h2>史赛克公司简介</h2>
<p>（免费报告）</p>
<p>史赛克公司是一家医疗科技公司。该公司通过两个部门运营，分别是医疗外科和神经技术，以及骨科和脊柱。骨科和脊柱部门提供用于全关节置换的植入物，如髋关节、膝关节和肩关节，以及创伤和四肢手术。</p>
<h2>精选文章</h2>
<ul>
<li>我们更看好的五只股票比史赛克更好</li>
<li>今日最大股票亏损者 - 今日最大百分比下跌者</li>
<li>开学购物达到 400 亿美元：现在值得关注的三只零售股票</li>
<li>什么是盈利惊喜？</li>
<li>谷歌母公司股票在躲避严厉的反垄断措施后大幅上涨</li>
<li>如何计算期权利润</li>
<li>为什么高通在经历几个月的滞后后表现优于英伟达</li>
</ul>
<p><strong>想看看其他对 SYK 持有的对冲基金吗？</strong> 请访问 HoldingsChannel.com 获取史赛克公司（NYSE:SYK - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVNZSw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVNZSw"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在史赛克吗？</h2>
<p>在考虑史赛克之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而史赛克并不在名单上。</p>
<p>虽然史赛克目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

史赛克

<p>Adage Capital Partners GP L.L.C. 在第一季度减少了对史赛克（NYSE:SYK）的持股比例，减持了 7.0%，出售了 10,044 股，剩余持有 134,347 股，市值为 5000 万美元。其他机构投资者也调整了他们的持仓。史赛克的股票开盘价为 388.14 美元，市值为 1483.9 亿美元。该公司报告第二季度每股收益为 3.13 美元，超出预期，并宣布每股季度分红为 0.84 美元，将于 10 月 31 日支付</p>

<p>Adage Capital Partners GP L.L.C. lowered its position in Stryker Corporation (NYSE:SYK - Free Report) by 7.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 134,347 shares of the medical technology company's stock after selling 10,044 shares during the quarter. Adage Capital Partners GP L.L.C.'s holdings in Stryker were worth $50,011,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Adage Capital Partners GP L.L.C. 在最近向美国证券交易委员会提交的 13F 表格中表示，在第一季度将其在史赛克公司（NYSE:SYK - 免费报告）的持股减少了 7.0%。该公司在季度内出售了 10,044 股后，持有 134,347 股这家医疗科技公司的股票。Adage Capital Partners GP L.L.C. 在史赛克的持股在最近一个季度末价值为 50,011,000 美元。</p>
</div><ul>
<li>If You Could Only Hold 3 Investments for Life, Consider These</li>
</ul>
<div class="lb-trans"><ul>
<li>如果你只能持有 3 项投资一辈子，请考虑这些</li>
</ul>
</div><p>Several other institutional investors have also recently made changes to their positions in SYK. Elefante Mark B bought a new stake in Stryker during the fourth quarter worth about $337,000. Mogy Joel R Investment Counsel Inc. lifted its stake in Stryker by 3.4% during the first quarter. Mogy Joel R Investment Counsel Inc. now owns 98,216 shares of the medical technology company's stock worth $36,561,000 after purchasing an additional 3,218 shares during the last quarter. Ferguson Wellman Capital Management Inc. lifted its stake in Stryker by 1.9% during the first quarter. Ferguson Wellman Capital Management Inc. now owns 174,871 shares of the medical technology company's stock worth $65,096,000 after purchasing an additional 3,341 shares during the last quarter. Harbor Capital Advisors Inc. bought a new stake in Stryker during the first quarter worth about $1,840,000. Finally, Mar Vista Investment Partners LLC lifted its stake in Stryker by 10.2% during the first quarter. Mar Vista Investment Partners LLC now owns 90,187 shares of the medical technology company's stock worth $33,572,000 after purchasing an additional 8,353 shares during the last quarter. Institutional investors own 77.09% of the company's stock.</p>
<div class="lb-trans"><p>其他几家机构投资者最近也对其在 SYK 的持仓进行了调整。Elefante Mark B 在第四季度购买了约 337,000 美元的新股份。Mogy Joel R Investment Counsel Inc. 在第一季度将其在史赛克的持股增加了 3.4%。Mogy Joel R Investment Counsel Inc. 现在持有 98,216 股这家医疗科技公司的股票，价值 36,561,000 美元，此前在上个季度又购买了 3,218 股。Ferguson Wellman Capital Management Inc. 在第一季度将其在史赛克的持股增加了 1.9%。Ferguson Wellman Capital Management Inc. 现在持有 174,871 股这家医疗科技公司的股票，价值 65,096,000 美元，此前在上个季度又购买了 3,341 股。Harbor Capital Advisors Inc. 在第一季度购买了约 1,840,000 美元的新股份。最后，Mar Vista Investment Partners LLC 在第一季度将其在史赛克的持股增加了 10.2%。Mar Vista Investment Partners LLC 现在持有 90,187 股这家医疗科技公司的股票，价值 33,572,000 美元，此前在上个季度又购买了 8,353 股。机构投资者目前持有该公司 77.09% 的股票。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖</h2>
</div><p>In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the company's stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the transaction, the director owned 3,222,108 shares in the company, valued at approximately $1,212,962,556.60. This represents a 5.84% decrease in their position. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Also, insider Viju Menon sold 500 shares of the company's stock in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $390.61, for a total value of $195,305.00. Following the transaction, the insider owned 12,511 shares in the company, valued at $4,886,921.71. This trade represents a 3.84% decrease in their position. The disclosure for this sale can be found here. 5.20% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他史赛克的新闻中，董事 Ronda E. Stryker 于 8 月 6 日星期三出售了 200,000 股公司的股票。该股票以平均价格 376.45 美元出售，总交易额为 75,290,000.00 美元。交易后，该董事在公司持有 3,222,108 股，估值约为 1,212,962,556.60 美元。这代表其持股减少了 5.84%。该交易已在向证券交易委员会的法律文件中披露，相关信息可通过 SEC 网站获取。此外，内部人士 Viju Menon 于 8 月 25 日星期一出售了 500 股公司的股票。该股票以平均价格 390.61 美元出售，总价值为 195,305.00 美元。交易后，该内部人士在公司持有 12,511 股，估值为 4,886,921.71 美元。这笔交易代表其持股减少了 3.84%。该销售的披露信息可以在这里找到。当前 5.20% 的股票由公司内部人士持有。</p>
</div><h2>Stryker Stock Performance</h2>
<div class="lb-trans"><h2>史赛克股票表现</h2>
</div><ul>
<li>3 Stocks Helping to Bring AI to Healthcare</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只股票助力人工智能进入医疗保健领域</li>
</ul>
</div><p>Stryker stock opened at $388.14 on Thursday. The company has a current ratio of 1.78, a quick ratio of 1.06 and a debt-to-equity ratio of 0.70. The firm has a 50-day moving average of $389.48 and a 200-day moving average of $379.51. The firm has a market cap of $148.39 billion, a P/E ratio of 51.41, a P/E/G ratio of 2.85 and a beta of 0.93. Stryker Corporation has a 1-year low of $329.16 and a 1-year high of $406.19.</p>
<div class="lb-trans"><p>史赛克股票在星期四开盘价为 388.14 美元。该公司的流动比率为 1.78，速动比率为 1.06，债务与股本比率为 0.70。该公司的 50 日移动平均线为 389.48 美元，200 日移动平均线为 379.51 美元。该公司的市值为 1483.9 亿美元，市盈率为 51.41，市盈增长比率为 2.85，贝塔值为 0.93。史赛克公司的 1 年最低价为 329.16 美元，1 年最高价为 406.19 美元。</p>
</div><p>Stryker (NYSE:SYK - Get Free Report) last posted its earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, topping analysts' consensus estimates of $3.07 by $0.06. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The company had revenue of $6.02 billion during the quarter, compared to analyst estimates of $5.92 billion. During the same period in the prior year, the business posted $2.81 earnings per share. Stryker's revenue for the quarter was up 11.1% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Sell-side analysts expect that Stryker Corporation will post 13.47 EPS for the current year.</p>
<div class="lb-trans"><p>史赛克（NYSE:SYK - 获取免费报告）最近一次发布财报是在 7 月 31 日星期四。这家医疗科技公司报告本季度每股收益为 3.13 美元，超出分析师一致预期的 3.07 美元，超出幅度为 0.06 美元。史赛克的净利润率为 12.25%，股本回报率为 23.94%。该公司本季度的收入为 60.2 亿美元，而分析师预期为 59.2 亿美元。在去年同期，该公司每股收益为 2.81 美元。史赛克本季度的收入同比增长 11.1%。史赛克已将其 2025 财年的每股收益指导设定为 13.400-13.600。卖方分析师预计史赛克公司本年度将发布 13.47 的每股收益。</p>
</div><h2>Stryker Announces Dividend</h2>
<div class="lb-trans"><h2>史赛克宣布分红</h2>
</div><ul>
<li>Boston Scientific: Why This MedTech Giant Isn’t Slowing Down</li>
</ul>
<div class="lb-trans"><ul>
<li>波士顿科学：为什么这家医疗科技巨头不会放慢脚步</li>
</ul>
</div><p>The company also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be issued a dividend of $0.84 per share. The ex-dividend date is Tuesday, September 30th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.9%. Stryker's dividend payout ratio is 44.50%.</p>
<div class="lb-trans"><p>该公司最近还宣布了一项季度分红，将于 10 月 31 日星期五支付。9 月 30 日星期二的股东将获得每股 0.84 美元的分红。除息日为 9 月 30 日星期二。这代表年化分红为 3.36 美元，分红收益率为 0.9%。史赛克的分红支付比率为 44.50%。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>Several brokerages have issued reports on SYK. Wall Street Zen raised Stryker from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research note on Friday, July 18th. Needham &amp; Company LLC raised their price objective on Stryker from $442.00 to $448.00 and gave the company a &#34;buy&#34; rating in a research note on Friday, August 1st. BTIG Research reaffirmed a &#34;buy&#34; rating on shares of Stryker in a research note on Monday, July 14th. Citigroup reaffirmed a &#34;buy&#34; rating and set a $455.00 price objective (up from $443.00) on shares of Stryker in a research note on Thursday, May 22nd. Finally, Evercore ISI raised their price objective on Stryker from $390.00 to $415.00 and gave the company an &#34;outperform&#34; rating in a research note on Tuesday, July 8th. Fifteen research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $430.10.</p>
<div class="lb-trans"><p>几家券商已对 SYK 发布了报告。华尔街 Zen 在 7 月 18 日星期五的研究报告中将史赛克的评级从 “持有” 上调至 “买入”。Needham &amp; Company LLC 在 8 月 1 日的研究报告中将史赛克的目标价从 442.00 美元上调至 448.00 美元，并给予该公司 “买入” 评级。BTIG Research 在 7 月 14 日星期一的研究报告中重申了对史赛克股票的 “买入” 评级。花旗集团在 5 月 22 日星期四的研究报告中重申了 “买入” 评级，并将史赛克股票的目标价设定为 455.00 美元（上调自 443.00 美元）。最后，Evercore ISI 在 7 月 8 日星期二的研究报告中将史赛克的目标价从 390.00 美元上调至 415.00 美元，并给予该公司 “跑赢大盘” 评级。十五位研究分析师对该股票给予了 “买入” 评级，四位给予了 “持有” 评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “适度买入”，共识目标价为 430.10 美元。</p>
</div><p><strong>Read Our Latest Stock Report on SYK</strong></p>
<div class="lb-trans"><p><strong>阅读我们最新的 SYK 股票报告</strong></p>
</div><h2>Stryker Profile</h2>
<div class="lb-trans"><h2>史赛克公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.</p>
<div class="lb-trans"><p>史赛克公司是一家医疗科技公司。该公司通过两个部门运营，分别是医疗外科和神经技术，以及骨科和脊柱。骨科和脊柱部门提供用于全关节置换的植入物，如髋关节、膝关节和肩关节，以及创伤和四肢手术。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Stryker</li>
<li>Biggest Stock Losers - Today’s Biggest Percentage Decliners</li>
<li>Back-to-School Shopping Hits $40B: 3 Retail Stocks to Watch Now</li>
<li>What is an Earnings Surprise?</li>
<li>Alphabet Stock Surges After Dodging Harsh Antitrust Remedies</li>
<li>How to Calculate Options Profits</li>
<li>Why Qualcomm Is Outperforming NVIDIA After Months of Lagging</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比史赛克更好</li>
<li>今日最大股票亏损者 - 今日最大百分比下跌者</li>
<li>开学购物达到 400 亿美元：现在值得关注的三只零售股票</li>
<li>什么是盈利惊喜？</li>
<li>谷歌母公司股票在躲避严厉的反垄断措施后大幅上涨</li>
<li>如何计算期权利润</li>
<li>为什么高通在经历几个月的滞后后表现优于英伟达</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding SYK?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 SYK 持有的对冲基金吗？</strong> 请访问 HoldingsChannel.com 获取史赛克公司（NYSE:SYK - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVNZSw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=SYK"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Stryker Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在史赛克吗？</h2>
</div><p>Before you consider Stryker, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑史赛克之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stryker wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而史赛克并不在名单上。</p>
</div><p>While Stryker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然史赛克目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Adage Capital Partners GP L.L.C.出售了 10,044 股史赛克公司股票$SYK